Publication Name	World Journal of Diabetes
Manuscript ID	90495
Country	Italy

Received	2023-12-05 15:39
Peer-Review Started	2023-12-05 15:39
To Make the First Decision
Return for Revision	2024-02-02 06:32
Revised	2024-02-15 09:20
Second Decision	2024-03-18 02:43
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-03-18 05:36
Articles in Press	2024-03-18 05:36
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-04-29 00:23
Publish the Manuscript Online	2024-05-10 11:51

ISSN	1948-9358 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: Https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Editorial
Article Title	Cardioprotective effects of glucagon-like peptide 1 receptor agonists in heart failure: Myth or truth?
Manuscript Source	Invited Manuscript
All Author List	Lorenzo Nesti and Domenico Trico
Funding Agency and Grant Number
Corresponding Author	Domenico Trico, MD, PhD, Assistant Professor, Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 67, Pisa 56126, Italy. domenico.trico@unipi.it
Key Words	Atherosclerosis; Cardiovascular system; Glucagon-like peptide-1; Heart failure; Tirzepatide; Type 2 diabetes; Ventricular function, Left
Core Tip	A growing body of evidence supports the potential cardioprotective properties of glucagon-like peptide 1 receptor agonists (GLP1-RAs) beyond glycemic control, especially in the context of cardiovascular disease. Although the effects of these drugs are consistent in reducing atherosclerosis-related diseases, there is an ongoing debate about the validity of the claim that GLP1-RAs have cardioprotective benefits in heart failure (HF)–a topic that sparks both enthusiasm and skepticism in the scientific and medical communities. Herein we provide a narrative review of the available evidence on the cardioprotective actions of GLP1-RAs in patients with HF, summarizing clinical findings and proposed mechanisms.
Publish Date	2024-05-10 11:51
Citation	Nesti L, Trico D. Cardioprotective effects of glucagon-like peptide 1 receptor agonists in heart failure: Myth or truth? World J Diabetes 2024; 15(5): 818-822
URL	https://www.wjgnet.com/1948-9358/full/v15/i5/818.htm
DOI	10.4239/wjd.v15.i5.818

Full Article (PDF)	WJD-15-818-with-cover.pdf
Full Article (Word)	WJD-15-818.docx
Manuscript File	90495_Auto_Edited-YJP.docx
Answering Reviewers	90495-Answering reviewers.pdf
Audio Core Tip	90495-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	90495-Conflict-of-interest statement.pdf
Copyright License Agreement	90495-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	90495-Language certificate.pdf
Peer-review Report	90495-Peer-review(s).pdf
Scientific Misconduct Check	90495-Bing-Li L-2.png
Scientific Editor Work List	90495-Scientific editor work list.pdf
CrossCheck Report	90495-CrossCheck.png
CrossCheck Report	90495-CrossCheck report.pdf